Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA yield high or low?
The EBITDA yield of 0.69% is 17% above its estimated 1-year average of 0.59%, near the high end of its estimated 1-year range (0.50%–0.69%).
As of 2026-10-06T18:47:30.842Z.
Calculation as of: 2026-10-06T18:47:30.842Z.
Quote observation: 2026-10-06T18:45:11.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 30dfce3917ca71ab065f09e043ba83ae01990a938fe51dfc801fb26557bc7c3c
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
0.69%
EBITDA YIELD AVG TTM
N/A
EBITDA YIELD AVG 3Y
N/A
EBITDA YIELD AVG 5Y
N/A
EBITDA YIELD AVG 10Y
N/A
EBITDA YIELD AVG 15Y
N/A
EBITDA YIELD AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
6.37%
median of 217 covered companies
CURRENT VS SECTOR MEDIAN
-89.17%
vs the sector median at left
Market Cap
$1.22B
EBITDA Yield
6.98%
TTM Avg
3.73%
3Y Avg
2.86%
5Y Avg
4.37%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Omada Health (OMDA) | $1.22B | 0.69% | N/A | N/A | N/A |
| Cronos Group Inc. (CRON)vs › | $1.22B | 3.58% | 5.34% | 5.34% | 5.34% |
| Innovage Holding Corp. (INNV)vs › | $1.22B | 6.98% | 3.73% | 2.86% | 4.37% |
| MannKind Corporation (MNKD)vs › | $1.21B | 1.92% | 3.43% | 3.63% | 3.63% |
| Tyra Biosciences, Inc. (TYRA)vs › | $1.21B | N/A | N/A | N/A | N/A |
| ORIC Pharmaceuticals, Inc. (ORIC)vs › | $1.20B | N/A | N/A | N/A | N/A |
| Kardigan, Inc. (KARD)vs › | $1.26B | N/A | N/A | N/A | N/A |
| Damora Therapeutics, Inc. (DMRA)vs › | $1.18B | N/A | N/A | N/A | N/A |
| Nektar Therapeutics (NKTR)vs › | $1.15B | N/A | 11.26% | 11.26% | 8.77% |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.14B | 11.19% | 12.87% | 11.35% | 9.45% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA YIELD |
|---|---|
| 2026-10-05 | 0.62% |
| 2026-10-02 | 0.64% |
| 2026-10-01 | 0.64% |
| 2026-09-30 | 0.63% |
| 2026-09-29 | 0.68% |
| 2026-09-28 | 0.68% |
| 2026-09-25 | 0.67% |
| 2026-09-24 | 0.67% |
| 2026-09-23 | 0.63% |
| 2026-09-22 | 0.61% |
| 2026-09-21 | 0.63% |
| 2026-09-18 | 0.64% |
| 2026-09-17 | 0.66% |
| 2026-09-16 | 0.67% |
| 2026-09-15 | 0.67% |
| 2026-09-14 | 0.64% |
| 2026-09-11 | 0.67% |
| 2026-09-10 | 0.60% |
| 2026-09-09 | 0.60% |
| 2026-09-08 | 0.58% |
| 2026-09-04 | 0.56% |
| 2026-09-03 | 0.58% |
| 2026-09-02 | 0.55% |
| 2026-09-01 | 0.56% |
| 2026-08-31 | 0.51% |
| 2026-08-28 | 0.54% |
| 2026-08-27 | 0.52% |
| 2026-08-26 | 0.53% |
| 2026-08-25 | 0.53% |
| 2026-08-24 | 0.53% |
| 2026-08-21 | 0.53% |
| 2026-08-20 | 0.54% |
| 2026-08-19 | 0.52% |
| 2026-08-18 | 0.53% |
| 2026-08-17 | 0.53% |
| 2026-08-14 | 0.53% |
| 2026-08-13 | 0.52% |
| 2026-08-12 | 0.53% |
| 2026-08-11 | 0.53% |
| 2026-08-10 | 0.50% |
